Products

Tsanangudzo:
prim-o-glucosylcimifugin ine simba rinopesana nekuputika.Chirevo cheiNOS uye COX-2 chinogona kuvharwa nekudzora JAK2 / STAT3 chiratidzo che transd.

Zvikamu zvinoenderana:
Kuratidzira nzira>> kusadzivirirwa uye kuzvimba>> nitric oxide synthase
Tsvagiridzo yemunda > > kuzvimba / kusadzivirirwa
Natural Products > > vamwe

Chinangwa:iNOS
COX-2

In Vitro Chidzidzo:
prim-o-glucosylglycine (POG) ndiyo yepamusoro-soro yekromone uye chimwe chezvinhu zvikuru zvinoshanda muFangfeng (RS).Prim-o-glucosylglycine inobata basa rinopesana nekuputika mune mbishi 264.7 macrophages nekudzivisa JAK2 / STAT3 transduction transduction uye inhibiting kutaura kweNOS uye COX-2.Iyo cytotoxicity yeprim-o-glucoside paLPS yakagadziriswa mbishi 264.7 macrophages yakayerwa.Shandisa LPS (1 μ G / ml) uye kuwedzera kuwanda kweprim-o-glucosylglycine (15, 50 uye 100 μ G / ml) kwemaawa makumi maviri nemana, uye kushanda kwesero kwakaongororwa neCCK-8 assay.Kuenzaniswa neDMSO inorapwa maseru (kutonga), maawa makumi maviri nemana uye kuratidzwa kune 15-100 μ Mushure me g / ml prim-o-glucoside, kushanda kwesero hakuna kukanganiswa zvakanyanya.Kuti udzidze anti-inflammatory effect ye prim-o-glucosylglycine, kana prim-o-glucosylglycine inogona kukanganisa NO synthesis yakaongororwa muLPS yakagadziriswa masero 264.7.Shandisa LPS (1 μ G / ml) uye zvakasiyana-siyana zveprim-o-glucosylglycine (15, 50 uye 100 μ G / ml) kwemaawa makumi maviri nemana.Iko kusungirirwa hakuna kuyerwa mutsika yepamusoro nekuita kwaGriess.Iko kusungirirwa kweasina mutsika yepamusoro yakawedzera zvakanyanya nekuratidzwa kweLPS, uye prim-o-glucoside yakadzivirirwa zvakanyanya LPS haina kugadzirwa nenzira inotsamira [1].
MuVivo Kudzidza
Bronchoalveolar lavage fluid (BALF) yakaunganidzwa maawa manomwe mushure mekutonga kwe lipopolysaccharide (LPS), uye chiyero checytokine muBALF chakayerwa neELISA.Kuenzaniswa neboka rekutonga, TNF muBALF- α, IL-1 β Uye IL-6 mazinga akawedzera zvakanyanya.Zvisinei, pretreatment ne prime-o-glucosylglycine (2.5, 5 kana 10 mg / kg) zvakanyanya pasi yakarongeka TNF- α, IL-1 β Uye IL-6 nenzira inoenderana nedosi (P <0.05, P <0.05, 0.01 ) [1].

Sero Kuedza
Sero kuverenga Kit (CCK-8) yakashandiswa kuona cytotoxic concentration yeprim-o-glucosylglycine.Muchidimbu, masero matsvuku e264.7 akabatwa ne1 patsime × Kuwanda kwemasero e104 akaiswa mumatsime e96 uye akaiswa usiku hwose.Zvadaro shandisa 1 μ Masero akakurudzirwa ne g/ml LPS uye akabatwa neakasiyana-siyana e-prim-o-glucosylglycine (15, 50 uye 100 μ g/ mL; Medchem express, Princeton, NJ, USA) kana DMSO kurapwa.Mushure mekuita incubation pa 37 ℃ kwemaawa makumi maviri nemana, CCK-8 solution yakawedzerwa kune rimwe nerimwe tsime uye yakavharidzirwa kweimwe awa.Absorbance yakayerwa pa450 nm uchishandisa microplate reader [1].

Animal Experiment
mbeva [1] BALB / C mbeva dzechirume, mavhiki masere ekuzvarwa, anorema anenge 18 kusvika 20g.Mbeva dzakakamurwa zvisina tsarukano mumapoka e5: boka rekutonga;LPS boka;LPS + prime-o-glucosylglycine (2.5, 5 kana 10mg / kg uremu hwemuviri).Prime-o-glucosylglycine yaishandiswa intraperitoneally.Mushure meawa 1, mbeva muboka reLPS uye LPS + prime-o-glucosylglycine boka rakapiwa 50 mg / L intranasal (mu) (200 mg / L) μ LLPs kuti iite kukuvara kwakanyanya kwemapapu.Iro mbeva dzekudzora dzakapihwa 50% intranasal (mu) isina LPS μ LPBS
[1]

Reference:
[1].Zhou J, nevamwe.Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response muRAW 264.7 Macrophages.Pharmacogn Mag.2017 Jul-Sep;13(51):378-384.
[2].Chen N, nevamwe.Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute mapapu kukuvara mumakonzo.Int Immunopharmacol.2013 Jun;16(2):139-47.